Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 3Terminated 1Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Leukemia, Myeloid, Acute 10Precursor Cell Lymphoblastic Leukemia-Lymphoma 5Myelodysplastic Syndromes 5Hodgkin Disease 5Leukemia, Biphenotypic, Acute 4Hematologic Neoplasms 4Leukemia, Myelomonocytic, Chronic 3Anemia, Refractory, with Excess of Blasts 3Sarcoma 2Rhabdomyosarcoma 2Neuroblastoma 2Multiple Myeloma 2Medulloblastoma 2Lymphoma, T-Cell 2Lymphoma, Non-Hodgkin 2Lymphoma, Mantle-Cell 2Lymphoma, Large B-Cell, Diffuse 2Lymphoma, Follicular 2Leukemia, Myelogenous, Chronic, BCR-ABL Positive 2Glioblastoma 2Burkitt Lymphoma 2Uterine Cervical Neoplasms 1Triple Negative Breast Neoplasms 1Teratoma 1Solid Tumors 1Sarcoma, Ewing 1Rhabdoid Tumor 1Recurrence 1Pyloric Stenosis, Hypertrophic 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1

Interventions

PM 01183 2pegylated granulocyte colony-stimulating factor 1pegfilgrastim 1pasireotide 1fludarabine phosphate 1fludarabine 1Zoledronic Acid 1Vincristine 1Temozolomide 1Mesna 1Irinotecan 1Injections 1Ifosfamide 1Granulocyte Colony-Stimulating Factor 1Filgrastim 1Doxorubicin 1Cyclophosphamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Desmoplastic Small Round Cell Tumor × Filgrastim × Clear all
NCT06709495 2026-02-19

Phase 1/2 Trial to Evaluate the Safety and Efficacy of PEEL-224 in Combination With Vincristine and Temozolomide in Adolescents and Young Adults With Relapsed or Refractory Sarcomas

Dana-Farber Cancer Institute

Phase 1/2 Recruiting
63 enrolled
Sarcoma

Rhabdomyosarcoma, Sarcoma, Sarcoma, Ewing, Osteosarcoma, Desmoplastic Small Round Cell Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡